These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 26419385)
1. Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Dudek M; Marcinkowska M; Bucki A; Olczyk A; Kołaczkowski M Metab Brain Dis; 2015 Dec; 30(6):1487-94. PubMed ID: 26419385 [TBL] [Abstract][Full Text] [Related]
2. Idalopirdine, a selective 5-HT Kotańska M; Lustyk K; Bucki A; Marcinkowska M; Śniecikowska J; Kołaczkowski M Metab Brain Dis; 2018 Jun; 33(3):733-740. PubMed ID: 29297106 [TBL] [Abstract][Full Text] [Related]
3. Idalopirdine as a treatment for Alzheimer's disease. Galimberti D; Scarpini E Expert Opin Investig Drugs; 2015; 24(7):981-7. PubMed ID: 26022777 [TBL] [Abstract][Full Text] [Related]
5. A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity. Dudek M; Knutelska J; Bednarski M; Nowiński L; Zygmunt M; Mordyl B; Głuch-Lutwin M; Kazek G; Sapa J; Pytka K PLoS One; 2015; 10(10):e0141327. PubMed ID: 26506439 [TBL] [Abstract][Full Text] [Related]
6. Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. Dudek M; Knutelska J; Bednarski M; Nowiński L; Zygmunt M; Kazek G; Mordyl B; Głuch-Lutwin M; Zaręba P; Kulig K; Sapa J Eur J Pharmacol; 2016 Apr; 776():146-55. PubMed ID: 26896778 [TBL] [Abstract][Full Text] [Related]
7. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807 [TBL] [Abstract][Full Text] [Related]
8. Aqueous extract of Chrysobalanus icaco leaves, in lower doses, prevent fat gain in obese high-fat fed mice. White PA; Cercato LM; Batista VS; Camargo EA; De Lucca W; Oliveira AS; Silva FT; Goes TC; Oliveira ER; Moraes VR; Nogueira PC; De Oliveira E Silva AM; Quintans-Junior LJ; Lima BS; Araújo AA; Santos MR J Ethnopharmacol; 2016 Feb; 179():92-100. PubMed ID: 26723470 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Effects and Mechanism of L-Citrulline on Anti-obesity by Appetite Suppression in Obese/Diabetic KK-Ay Mice and High-Fat Diet Fed SD Rats. Kudo M; Yoshitomi H; Momoo M; Suguro S; Yamagishi Y; Gao M Biol Pharm Bull; 2017; 40(4):524-530. PubMed ID: 28381807 [TBL] [Abstract][Full Text] [Related]
10. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys. Wagner JD; Zhang L; Kavanagh K; Ward GM; Chin JE; Hadcock JR; Auerbach BJ; Harwood HJ J Pharmacol Exp Ther; 2010 Oct; 335(1):103-13. PubMed ID: 20605903 [TBL] [Abstract][Full Text] [Related]
11. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368 [TBL] [Abstract][Full Text] [Related]
12. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Mashiko S; Ishihara A; Iwaasa H; Moriya R; Kitazawa H; Mitobe Y; Ito J; Gomori A; Matsushita H; Takahashi T; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A Obesity (Silver Spring); 2008 Jul; 16(7):1510-5. PubMed ID: 18421274 [TBL] [Abstract][Full Text] [Related]
13. Antiobesity effect of Safoof Mohazzil, a polyherbal formulation, in cafeteria diet induced obesity in rats. Gupta P; Mehla J; Gupta YK Indian J Exp Biol; 2012 Nov; 50(11):776-84. PubMed ID: 23305028 [TBL] [Abstract][Full Text] [Related]
14. Antiobesity activities of indole-3-carbinol in high-fat-diet-induced obese mice. Chang HP; Wang ML; Chan MH; Chiu YS; Chen YH Nutrition; 2011 Apr; 27(4):463-70. PubMed ID: 21392705 [TBL] [Abstract][Full Text] [Related]
15. The histamine H Kotańska M; Kuder KJ; Szczepańska K; Sapa J; Kieć-Kononowicz K Naunyn Schmiedebergs Arch Pharmacol; 2018 Aug; 391(8):875-881. PubMed ID: 29802412 [TBL] [Abstract][Full Text] [Related]
16. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease. Calhoun A; Ko J; Grossberg GT Expert Opin Emerg Drugs; 2017 Mar; 22(1):101-105. PubMed ID: 28253832 [TBL] [Abstract][Full Text] [Related]
17. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Fukuda-Tsuru S; Kakimoto T; Utsumi H; Kiuchi S; Ishii S Eur J Pharmacol; 2014 Jan; 723():207-15. PubMed ID: 24309217 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Liu YL; Heal DJ; Stock MJ Int J Obes Relat Metab Disord; 2002 Sep; 26(9):1245-53. PubMed ID: 12187403 [TBL] [Abstract][Full Text] [Related]
20. S 23521 decreases food intake and body weight gain in diet-induced obese rats. Claret M; Corominola H; Canals I; Nadal B; Chavanieu A; Pfeiffer B; Renard P; Gorostiaga C; Delagrange P; Grassy G; Gomis R Obes Res; 2004 Oct; 12(10):1596-603. PubMed ID: 15536223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]